AstraZeneca's Full Data From Phase 3 Tulip-SC Trial Show That Subcutaneous Saphnelo (Anifrolumab) Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Disease Activity Vs. Placebo in Systemic Lupus Erythematosus Patients

Benzinga·01/06/2026 08:36:36

語音播報

Saphnelo enabled oral corticosteroid reduction while maintaining clinical response in a key secondary endpoint
Patients achieved remission with Saphnelo as demonstrated in an exploratory endpoint